A61K2800/10

Composition of lipoamino acids and alkanediols, process for the preparation thereof, and cosmetic or pharmaceutical composition resulting therefrom

Disclosed are a new composition of lipoamino acids and alkanediols, a process for the preparation thereof, and a cosmetic or pharmaceutical composition resulting therefrom.

Enzyme exhibiting alpha-1,6-glucosyl transfer activity

The present invention relates to an enzyme having α-1,6-glucosyl transfer activity, which can use a partially degraded starch product as a substrate and is heat resistant and suitable for industrial applications; an enzyme preparation for use in manufacturing α-1,6-glucan, comprising the enzyme as an active ingredient; and a method for manufacturing α-1,6-glucan using the enzyme or enzyme preparation. The present invention provides an enzyme having α-1,6-glucosyl transfer activity, which is any one of proteins (a), (b), and (c): (a) a protein consisting of an amino acid sequence of SEQ ID NO: 3; (b) a protein consisting of an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 3; and (c) a protein consisting of an amino acid sequence in which one or several amino acid(s) have been substituted, inserted, deleted and/or added in the amino acid sequence of SEQ ID NO: 3.

A COOLING PREPARATION
20230059747 · 2023-02-23 ·

Suggested is a cooling preparation comprising phenylalkenals and homovanillic acid esters.

Sulfate-Free Surfactant System
20230053407 · 2023-02-23 ·

Provided is a sulfate-free surfactant system which is particularly suitable for use in personal hygiene products. The sulfate-free surfactant system comprises a liquid comprising an organic phase and a solvent wherein the organic phase comprises glyceride and surfactant and the liquid comprises: 4-40 wt % glyceride wherein the glyceride is the condensation reaction product of at least 1.10 moles of a mixture of acids to no more than 2.1 moles of mixture of acids per mole of glycerin; wherein mixture of acids comprises: at least 0.275 to no more than 0.990 moles of a first acid comprising a branched acid with 16-20 aliphatic carbons; at least 0.250 to no more than 0.810 moles of a second acid comprising an alkyl acid with 9-11 carbons; and at least 0.250 to no more than 0.810 moles of a third acid comprising an alkyl acid with 7-9 carbons wherein the third acid has a lower molecular weight than the second acid; and 6-45 wt % surfactant; and wherein the liquid has a BYV of at least 50 dyn/cm.sup.2.

DELIVERY CARRIER INTO CELL
20230055665 · 2023-02-23 ·

[Problem to be Solved]

Provided is a delivery carrier into the cell having high antioxidant activity, intracellular absorbability, intracellular disintegration property, stability and safety, which have high delivery property of the active ingredient to cell and living tissues.

[Solution]

The delivery carrier into cells includes a vitamin derivative with co-activation of both autophagy-related genes and protease synthesis genes, a polymer molecule containing stimulatory reactivity, an emulsion stabilizer, an active ingredient, and a lipid, thereby providing a delivery carrier into cells with high delivery properties of the active ingredient to cells and living tissues.

AN ANTIMICROBIAL MIXTURE
20220362119 · 2022-11-17 ·

Suggested is an antimicrobial mixture comprising or consisting of (a) at least one monocyclic sesquiterpene alcohol, (b) at least one active selected from the group consisting of 4-hydroxyacetophenone, sorbitan caprylate, cocamidopropyl PG-dimonium chloride phosphate, tetrasodium glutamate diacetate, glyceryl caprylate and glyceryl caprate, and optionally (c) at least one additional antimicrobial agent different from components (a) and (b).

CITRONELLOL ALKOXYLATE SURFACTANTS
20230058226 · 2023-02-23 ·

The present disclosure is directed to novel derivatives of citronellol and polycitronellol, particularly alkoxylated derivatives of citronellol and polycitronellol, and methods of making them, compositions comprising them, and methods for using them, particularly as surfactants.

ROMO1-DERIVED ANTIMICROBIAL PEPTIDES INCLUDING LYSINE SUBSTITUTION AND VARIANTS THEREOF
20220362332 · 2022-11-17 ·

The present invention relates to antimicrobial peptides derived from Romo1 protein, and provides various peptides having the amino acid sequence of the α-helix 2 region of the Romo1 protein and an antibacterial composition containing each of the peptides, as a result of confirming that the peptides have antibacterial activity against gram-positive, gram-negative and multidrug-resistant bacteria. The Romo1-derived peptides and variants thereof have better bactericidal capability against various types of bacteria and multidrug-resistant bacteria than existing antibiotics and antibiotic peptides, and have antibacterial activity against various bacteria in blood vessels, and are novel antibiotics that may be provided as substances for the prevention or treatment of a wide range of bacterial infectious diseases. A composition containing the antimicrobial peptide of the present invention is suitable for various applications, including drugs, quasi-drugs, food and feed additives, pesticides and cosmetic additives, to prevent or treat infectious diseases.

Gold nanoparticles and ecological method of production
11583585 · 2023-02-21 · ·

A method of preparing biocompatible and stable gold nanoparticles comprises preparing at least one flavonoid-rich plant extract, and mixing at least one of the plant extracts with an aqueous solution of at least one gold salt. The flavonoid-rich plant extract is an extract of Hubertia ambavilla or Hypericum lanceolatum. The gold nanoparticles may be used for medical and/or cosmetic purposes.

Immunomodulatory composition comprising lactobacillus-derived extracellular vesicles

The present specification discloses an immunomodulatory composition comprising lactobacillus-derived extracellular vesicles as an active ingredient. The lactobacillus may be Lactobacillus plantarum. The composition has the effects of inducing differentiation into M2-type macrophages and reducing expression of at least one member selected from the group consisting of CCR2, SOCS3 and HLA-DRα, which are M1-type macrophage differentiation markers.